The main objective of this study is to assess the anti-tumor activity of cimetidine and vitamin C via mitigating the tumor-associated mast cell mediators in the TME and inhibiting the activation of the PI3K/AKT/mTOR trajectory. Here, AKT1 is linked to neoplasm.